Latest news with #anti-cancer
Yahoo
03-08-2025
- Health
- Yahoo
Common sweetener could hold untapped potential to fight aggressive cancer, study finds
A household sweetener could hold the potential to create an anti-cancer treatment. New research from Hiroshima University in Japan revealed that stevia leaf extract could help fight pancreatic cancer cells. The leaves of the stevia plant (Stevia rebaudiana) are used to make stevia extract, a naturally sweet substance commonly used as a sugar substitute. Two Cancer Drugs Show Promise In Reversing Alzheimer's Devastating Effects The study, published in the International Journal of Molecular Sciences, investigated the anti-cancer properties of stevia leaf extract when it is fermented with a certain strain of bacteria. In laboratory research, the fermented extract exhibited "significantly enhanced antioxidant activity and cytotoxicity" against pancreatic cancer cells, the researchers revealed. Read On The Fox News App This led them to believe that this substance could serve as a "promising candidate for pancreatic cancer treatment." Paul E. Oberstein, M.D., medical oncologist and assistant director of the Pancreatic Cancer Center at NYU Langone Perlmutter Cancer Center, shared his thoughts in an interview with Fox News Digital. Ancient 'Pharaoh's Curse' Fungus Shows Promise In Killing Cancer Cells "This is an interesting study because it evaluated something derived from a natural plant (stevia) and showed that it may have utility in stopping cancer cells from growing in the laboratory," he said. "As the authors point out, the actual stevia plant does not seem to have any benefit for stopping cancer, so they had to use a chemical process to change the plant and make it stronger with a fermentation process." Oberstein recommended approaching this with caution, as it is unknown whether altering the plant will lead to side effects or toxicity. The study was not performed on humans, so there is "still a lot that's unknown about whether this will help patients," the oncologist added. As stevia extract alone does not have an impact on cancer cells, Oberstein said these findings most likely will not lead to any immediate changes in treatment plans. "The study suggests that if the stevia can be changed in the lab, it may have an impact, so hopefully they will further test this and determine whether this effect happens when tested in people and if it doesn't cause new side effects," he added. "I hope the researchers keep testing this in various formats and in people." Dr. Kristen Arnold, a surgical oncologist and pancreatic cancer specialist at the Orlando Health Cancer Institute, reacted to these study findings in a separate interview with Fox News Digital. "Pancreatic cancer is a very aggressive malignancy," she said. "And we know that even with the most aggressive of therapies, unfortunately, our outcomes are not good." "As a pancreatic cancer community, we spend a lot of time and there's a lot of ongoing effort into trying to find better modalities to treat this disease." Although more research is needed to confirm these preliminary findings, Arnold said she is encouraged by the study. Click Here To Sign Up For Our Health Newsletter "I think the data's very early to know if it's ultimately going to be a game-changer, but it's very exciting to know that we're finding some positive pre-clinical data," she said. "This is the process of how we discover new treatments – some of which turn out to be absolute game-changers and make dramatic changes in the lives of our patients." "Not all of it pans out, but it's a process of discovery," Arnold added. For those with pancreatic cancer, Arnold recommends seeking out appropriate clinical trial opportunities as new science develops. For more Health articles, visit "The clinical trials are ultimately what determine how we treat patients on a day-to-day basis," she added. Fox News Digital reached out to the study authors for article source: Common sweetener could hold untapped potential to fight aggressive cancer, study finds Solve the daily Crossword
Fox News
02-08-2025
- Health
- Fox News
Common sweetener could hold untapped potential to fight aggressive cancer, study finds
A household sweetener could hold the potential to create an anti-cancer treatment. New research from Hiroshima University in Japan revealed that stevia leaf extract could help fight pancreatic cancer cells. The leaves of the stevia plant (Stevia rebaudiana) are used to make stevia extract, a naturally sweet substance commonly used as a sugar substitute. The study, published in the International Journal of Molecular Sciences, investigated the anti-cancer properties of stevia leaf extract when it is fermented with a certain strain of bacteria. In laboratory research, the fermented extract exhibited "significantly enhanced antioxidant activity and cytotoxicity" against pancreatic cancer cells, the researchers revealed. This led them to believe that this substance could serve as a "promising candidate for pancreatic cancer treatment." Paul E. Oberstein, M.D., medical oncologist and assistant director of the Pancreatic Cancer Center at NYU Langone Perlmutter Cancer Center, shared his thoughts in an interview with Fox News Digital. "This is an interesting study because it evaluated something derived from a natural plant (stevia) and showed that it may have utility in stopping cancer cells from growing in the laboratory," he said. "As the authors point out, the actual stevia plant does not seem to have any benefit for stopping cancer, so they had to use a chemical process to change the plant and make it stronger with a fermentation process." "This is the process of how we discover new treatments – some of which turn out to be absolute game-changers." Oberstein recommended approaching this with caution, as it is unknown whether altering the plant will lead to side effects or toxicity. The study was not performed on humans, so there is "still a lot that's unknown about whether this will help patients," the oncologist added. As stevia extract alone does not have an impact on cancer cells, Oberstein said these findings most likely will not lead to any immediate changes in treatment plans. "The study suggests that if the stevia can be changed in the lab, it may have an impact, so hopefully they will further test this and determine whether this effect happens when tested in people and if it doesn't cause new side effects," he added. "I hope the researchers keep testing this in various formats and in people." Dr. Kristen Arnold, a surgical oncologist and pancreatic cancer specialist at the Orlando Health Cancer Institute, reacted to these study findings in a separate interview with Fox News Digital. "Pancreatic cancer is a very aggressive malignancy," she said. "And we know that even with the most aggressive of therapies, unfortunately, our outcomes are not good." "As a pancreatic cancer community, we spend a lot of time and there's a lot of ongoing effort into trying to find better modalities to treat this disease." Although more research is needed to confirm these preliminary findings, Arnold said she is encouraged by the study. "I think the data's very early to know if it's ultimately going to be a game-changer, but it's very exciting to know that we're finding some positive pre-clinical data," she said. "This is the process of how we discover new treatments – some of which turn out to be absolute game-changers and make dramatic changes in the lives of our patients." "Not all of it pans out, but it's a process of discovery," Arnold added. For those with pancreatic cancer, Arnold recommends seeking out appropriate clinical trial opportunities as new science develops. "The clinical trials are ultimately what determine how we treat patients on a day-to-day basis," she added. Fox News Digital reached out to the study authors for comment.
BBC News
01-08-2025
- Health
- BBC News
Cambridgeshire man died after fake deworming drug cancer claims
A man died after taking a deworming drug for animals after he saw fake claims online about it having anti-cancer properties, an inquest Redpath, 45, died nearly two weeks after being admitted to Addenbrooke's Hospital in Cambridge with liver problems in April last had bought the drug fenbendazole - which is not licensed for human consumption - online from a supplier in partner told the inquest she believed a "warning should be made" about the danger of the drug. The inquest at Lawrence Court in Huntingdon, Cambridgeshire, was told Mr Redpath had a history of drug and excess alcohol use and was admitted to hospital complaining of jaundice and coroner, Caroline Jones, said Mr Redpath told the doctors that he had seen "videos on social media sites about [fenbendazole's] supposed anti-cancer properties". "Fenbendazole is not licensed for human consumption and is more commonly used in animals for the treatment of worms and parasitic infections," she said. Online falsehoods Dr Gwilym Webb, a consultant hepatologist at Addenbrooke's, told the court he believed Mr Redpath "had been taking [fenbendazole] for around three-and-a-half weeks prior to coming to hospital".He said it was his understanding there was "no proven benefit for taking fenbendazole for treating cancer in humans".Ms Jones said tests on Mr Redpath "showed that he was suffering from an acute liver injury on a background of cirrhosis due to his previous alcohol excess."She said it was "thought likely that the fenbendazole used over a prolonged period in high doses was the primary cause of the acute injury".The court heard his condition deteriorated but he was not suitable for a liver Webb said to be considered for a transplant excess alcohol use must have ceased for at least three months - in this case it was a few weeks - and "uncontrolled addiction to other substances is considered a barrier".Mr Redpath died on 29 April and his cause of death was determined as liver and renal failure due to fenbendazole-induced liver injury on a background of alcohol-related Jones recorded his death was as a result of misadventure, adding she was concerned that false claims of fenbendazole having anti-cancer properties could "be so widely available online" and would write to the local public health for more data about the issue. Follow Cambridgeshire news on BBC Sounds, Facebook, Instagram and X.
Yahoo
22-07-2025
- Business
- Yahoo
Kaida BioPharma Participates in the Virtual Investor 'What's Your Story' Summer Spotlight On-Demand Conference
– Video webcast now available on-demand FORT LAUDERDALE, FL, July 22, 2025 (GLOBE NEWSWIRE) -- Kaida BioPharma ('Kaida' or the 'Company'), an early-stage pharma company dedicated to advancing targeted anti-cancer therapies to address hormone-driven cancers affecting women, today announced Stella Vnook, PhD, Co-Founder of Kaida, participated in the Virtual Investor 'What's Your Story' Summer Spotlight On-Demand Conference. For the event, Dr. Vnook dove deeper into her dedication to the Company, how she got to where she is today and provided insight into why she is so passionate about the Company's program in development. The on-demand video webcast is now available on About Kaida BioPharmaKaida BioPharma was founded on the research principles and clinical evidence of the therapeutic benefit of blocking the binding of prolactin (PRL), a multifunctional hormone, to its receptor (PRLR), given their roles as growth factors in tumor growth and proliferation. The Company's lead product candidate KAD101 is a growth hormone antagonist designed to selective and effectively block the tumoral PRL/PRLR axis which has been shown to induce programmed cell death (autophagy) in gynecologic tumors. The Company is collaborating closely with Dr. John Langenheim, professor at Thomas Jefferson University, and Dr. Anil Sood, professor and vice chair for translational research in the departments of gynecologic oncology and cancer biology at MD Anderson Cancer Center, who have both published extensive research on prolactin and its role as a growth factor in tumor growth and progression and the potential therapeutic benefit of KAD101. Kaida is dedicated to providing a new hope for patients with treatment-resistant gynecological cancers. The Company's mission is to develop innovative therapies that target the specific needs of those patients, offering a medical treatment that can make a significant difference. For more information, please visit ContactJenene ThomasChief Executive OfficerJTC Team, LLCT: 908.824.0775E: kaida@ Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
22-07-2025
- Business
- Yahoo
Kaida BioPharma Participates in the Virtual Investor 'What's Your Story' Summer Spotlight On-Demand Conference
– Video webcast now available on-demand FORT LAUDERDALE, FL, July 22, 2025 (GLOBE NEWSWIRE) -- Kaida BioPharma ('Kaida' or the 'Company'), an early-stage pharma company dedicated to advancing targeted anti-cancer therapies to address hormone-driven cancers affecting women, today announced Stella Vnook, PhD, Co-Founder of Kaida, participated in the Virtual Investor 'What's Your Story' Summer Spotlight On-Demand Conference. For the event, Dr. Vnook dove deeper into her dedication to the Company, how she got to where she is today and provided insight into why she is so passionate about the Company's program in development. The on-demand video webcast is now available on About Kaida BioPharmaKaida BioPharma was founded on the research principles and clinical evidence of the therapeutic benefit of blocking the binding of prolactin (PRL), a multifunctional hormone, to its receptor (PRLR), given their roles as growth factors in tumor growth and proliferation. The Company's lead product candidate KAD101 is a growth hormone antagonist designed to selective and effectively block the tumoral PRL/PRLR axis which has been shown to induce programmed cell death (autophagy) in gynecologic tumors. The Company is collaborating closely with Dr. John Langenheim, professor at Thomas Jefferson University, and Dr. Anil Sood, professor and vice chair for translational research in the departments of gynecologic oncology and cancer biology at MD Anderson Cancer Center, who have both published extensive research on prolactin and its role as a growth factor in tumor growth and progression and the potential therapeutic benefit of KAD101. Kaida is dedicated to providing a new hope for patients with treatment-resistant gynecological cancers. The Company's mission is to develop innovative therapies that target the specific needs of those patients, offering a medical treatment that can make a significant difference. For more information, please visit ContactJenene ThomasChief Executive OfficerJTC Team, LLCT: 908.824.0775E: kaida@ Sign in to access your portfolio
